ProPhase Labs (PRPH) invites investors to webinar on high-growth healthcare assets

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

ProPhase Labs, Inc. filed a current report to highlight an investor-focused communication event. On February 2, 2026, the company issued a press release inviting investors to a webinar scheduled for February 3, 2026 at 4:15 p.m. Eastern Time.

The webinar was intended to provide insight into ProPhase’s portfolio of high-growth healthcare assets and included a live question-and-answer session with attendees. The press release containing additional details about the event is furnished as Exhibit 1.1 to the report.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

02/13/2026 - 05:15 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 2, 2026

PROPHASE LABS, INC.

(Exact name of Company as specified in its charter)

Delaware

000-21617

23-2577138

(State or other jurisdiction

of incorporation )

(Commission

File Number)

(I.R.S. Employer

Identification No.)

626 RXR Plaza, 6th Floor

Uniondale, New York

11556

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (516) 989-0763

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14(d)-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Exchange Act:

Title of Each Class		Trading Symbol		Name of Each Exchange of Which Registered
Common Stock, par value $0.0005		PRPH		OTC ID

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

The Securities and Exchange Commission requires disclosure of material changes and events that the registrant deems of importance to security holders via Form 8-K filings. On February 2, 2026, ProPhase Labs, Inc. (“The Company”) issued a press release inviting investors to a webinar on Tuesday, February 3, 2026, at 4:15pm ET. The event allowed attendees to gain an insight into ProPhase’s dynamic portfolio of high-growth healthcare assets and included a live question and answer session.

A copy of the press release, including further details, is furnished as Exhibit 1.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

1.1	Press Release dated February 2, 2026.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ProPhase Labs, Inc.

By:	/s/ Ted Karkus
	Ted Karkus
	Chairman of the Board and Chief Executive Officer

Date: February 13, 2026

Source: View Original Filing on SEC EDGAR

FAQ

What did ProPhase Labs (PRPH) disclose in its latest 8-K filing?

ProPhase Labs disclosed that it issued a press release on February 2, 2026 inviting investors to a webinar. The event focused on its portfolio of high-growth healthcare assets and included a live Q&A, with the release filed as Exhibit 1.1.

When was the ProPhase Labs (PRPH) investor webinar scheduled?

The ProPhase Labs investor webinar was scheduled for Tuesday, February 3, 2026 at 4:15 p.m. Eastern Time. The 8-K notes that the event would offer insight into the company’s high-growth healthcare assets and provide a live question-and-answer session for attendees.

What was the purpose of the ProPhase Labs (PRPH) investor webinar?

The webinar aimed to give investors insight into ProPhase Labs’ dynamic portfolio of high-growth healthcare assets. It also included a live question-and-answer session, allowing attendees to engage directly and seek clarification on aspects of the company’s healthcare-related business activities.

How did ProPhase Labs (PRPH) communicate details of the investor webinar?

ProPhase Labs issued a press release on February 2, 2026 inviting investors to the webinar. That press release, which contains further details about the event and logistics, is furnished in the 8-K filing as Exhibit 1.1 for public reference.

Which exhibit in the ProPhase Labs (PRPH) 8-K relates to the webinar announcement?

Exhibit 1.1 to the 8-K is a press release dated February 2, 2026 that invites investors to the webinar. The exhibit includes additional information about the event, which focuses on ProPhase’s high-growth healthcare assets and features a live Q&A session.

Does the ProPhase Labs (PRPH) 8-K include financial results or earnings data?

The 8-K focuses on an investor webinar invitation and related press release, not on financial results. It highlights the event’s goal of presenting ProPhase’s high-growth healthcare assets and notes that the detailed press release is attached as Exhibit 1.1.

Filing Exhibits & Attachments

5 documents